May 17, 2020

MediciNova Q2 net loss $2.3 mln

Biopharmaceutical company
publicly trade biopharmaceutical
2 min
MedicNova Q2 net loss $2.3 mln
MediciNova Inc said it has reported a net loss of $2.3 million or $0.14 per share in second quarter ended June 30, 2012. The biopharmaceutical company...

MediciNova Inc said it has reported a net loss of $2.3 million or $0.14 per share in second quarter ended June 30, 2012. The biopharmaceutical company had reported a net loss of $4.7 million or $0.31 a share in the corresponding period last year.

The research and development service revenue pertaining to the Kissei services agreement was $0.5 million.

In the second quarter, MediciNova’s R&D expenses stood at $1.5 million compared to $2.0 million posted in the same quarter last year. The decline in the R&D expenses was on account of a decrease in the spending on the prioritized asset MN-221 for treating acute exacerbations of asthma and COPD. Another reason for the plunge in R&D expenses is the lower stock based compensation expense in the most recent quarter.

For the quarter ended June 30, 2012, the general and administrative expenses fell by $1.3 million due to the decrease in the stock-based compensation expense, partially offset by increase in compensation expense pertaining to the bonus of employees.

The company had $7.3 million in cash and cash equivalents as of June 30, 2012, as against $15.1 million of cash and cash equivalents at December 31, 2011.

MediciNova is a publicly traded biopharmaceutical company founded on acquisition of developing novel, small-molecule therapeutics for treating diseases with unmet needs with a commercial focus on the U.S. market.

Share article

Jun 17, 2021

Dexcom: changing the lives of people with type 1 diabetes

3 min
British actress Nina Wadia OBE tells us how her son's life has changed since using glucose monitoring system Dexcom

It is estimated that 9.3% of adults around the world are living with type 1 diabetes, which amounts to a total of 463 million people. A further 1.1 million children and adolescents under the age of 20 are living with the condition. 

Unlike the more prevalent type 2 diabetes, where the body still produces insulin and symptoms develop slowly, people with type 1 diabetes need regular insulin injections or pumps, and must monitor their sugar levels frequently. 

In recent years a number of remote glucose monitoring systems have become available that patients can use at home. These work with a sensor, usually placed under the skin, that measures glucose levels every few minutes. This information is then transmitted wirelessly to a device like a smartphone or tablet, which can then be shared with their clinician. 

British actress Nina Wadia's son Aidan, 14, has type 1 diabetes, and has been managing his condition using Dexcom, a glucose monitoring system used by patients all over the world. Here Wadia explains how Dexcom has improved their lives. 

As a parent of someone with type 1 diabetes, what is your day-to-day life like?
Being able to take a breath, think and pivot constantly without getting frustrated becomes an essential mindset because sometimes it feels like each day is determined to be different from the day before. Whatever worked yesterday is going to misfire today. 

Which areas of yours and Aidan’s life are most impacted by diabetes? 
The one thing that you have to fight hard to reclaim is spontaneity, especially when it comes to food and exercise. It’s only when this is taken do you realise how essential each one is. You can be flexible and there are no real limits, but only in the sense that a great athlete can be flexible without limits because they’ve trained super hard to be that way. So we’ve all had to become athletes when it comes to being spontaneous.

How has Dexcom helped you and Aidan? 
Dexcom has brought future science fiction to real life today. The continuous glucose monitoring system is tiny, sits discreetly on his body and gives him a ten-day breather between sensor changes, so it's goodbye finger-pricking seven times daily. 

Dexcom is totally active at a grass roots level and for Diabetes Awareness has pledged to donate £2,000 if #DexcomDiabetesStories and/or #DexcomWarriorStories is shared 200 times! I’ll be sharing more on social media and would love to hear how other families are winning their fights.

Maybe most importantly Dexcom is trying to introduce a reimbursement programme for type 1 diabetes  patients which will give greater access to modern, life changing hi-tech. I want to spread the word on the importance of accessing it through this campaign. 

If you compared your life today with how it was before Aidan was using Dexcom, what has changed? 
It's always working, which lets him take his mind off diabetes for longer stretches. It also lets me get off his back. We both receive alerts so I no longer have to pester him by asking him what his number is, and especially importantly, I don’t have to wake him at night to prick his finger if I’m worried. Dexcom gave us back our sleep!

Share article